Dutogliptin tartrate is under clinical development by Recardio and currently in Phase II for Post-Myocardial Infarction. According to GlobalData, Phase II drugs for Post-Myocardial Infarction have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dutogliptin tartrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dutogliptin tartrate overview

Dutogliptin tartrate (REC-01) is under development for the treatment of acute and post myocardial infarction. The therapeutic candidate is formulated as solution and administered through subcutaneous route. The drug candidate is a DPP-IV inhibitor and is also given in combination with G-CSF.

Recardio overview

Recardio is a life science company that focuses on drug-based regenerative therapeutic modalities for treatments of cardiovascular diseases. The company is headquartered in San Francisco, California, the US

For a complete picture of Dutogliptin tartrate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.